E75.02 Tay-Sachs disease

Name of the Condition

• Tay-Sachs disease (ICD-10 Code: E75.02)

Summary

Tay-Sachs disease is a rare inherited lysosomal storage disorder characterized by the accumulation of GM2 ganglioside in neurons and other cells. This buildup disrupts normal cellular function, particularly affecting the nervous system. The condition is part of a broader group of sphingolipid metabolism disorders and presents with progressive neurological decline.

Causes

Tay-Sachs disease results from genetic mutations that impair the activity of enzymes involved in GM2 ganglioside breakdown. The condition is caused by defects in the HEXA gene, which encodes an enzyme necessary for lipid metabolism. Inheritance is typically autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of Tay-Sachs disease or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies (e.g., certain populations with increased prevalence of the disorder).

Symptoms

• Progressive neurological deterioration, including developmental delay or regression.
• Muscle weakness, hypotonia, or spasticity.
• Seizures or abnormal eye movements.
• Loss of motor skills or speech.
• Cherry-red spots in the retina (in some cases).

Diagnosis

Diagnosis involves clinical evaluation, genetic testing for HEXA gene mutations, and biochemical assays to measure enzyme activity. Imaging studies, such as MRI, may show characteristic brain changes. Newborn screening or carrier testing may be performed in high-risk populations.

Treatment Options

Treatment is primarily supportive, focusing on managing symptoms and improving quality of life. This may include medications for seizures, physical therapy, and nutritional support. No cure exists, but research into enzyme replacement and gene therapy is ongoing.

Prognosis and Follow-Up

Prognosis is poor, with most affected individuals not surviving beyond early childhood. Follow-up care involves regular neurological assessments, monitoring for complications, and supportive care to address developmental and physical needs.

Complications

• Severe neurological impairment.
• Respiratory complications due to muscle weakness.
• Feeding difficulties and nutritional deficiencies.
• Increased risk of infections.

Lifestyle & Prevention

• Genetic counseling for families with a history of the disorder.
• Carrier screening for at-risk populations.
• Prenatal testing options for known carriers.

When to Seek Professional Help

Seek immediate medical attention if symptoms of developmental regression, seizures, or significant neurological decline are observed, especially in infants or young children.

Tips for Medical Coders

Document the clinical presentation, genetic testing results, and any associated complications to support accurate coding. Ensure the code E75.02 is used when Tay-Sachs disease is confirmed, and include relevant details about the patient’s condition and management in the medical record.